Patent · US Active

Procoagulant antibodies

US12084512B2 · kind B2 · utility

0Cited by

8References

5Claims

0Family size

Assignee

Novo Nordisk A/S · DK

Inventors

Karina Thorn · Farum, DK
Bjarne Gram Hansen · Copenhagen, DK
Laust Bruun Johnsen · Skodsborg, DK
Mikkel Nors Harndahl · Roskilde, DK
Zhiru Yang · Beijing, CN
Henrik Oestergaard · Søgård, DK
Per J. Greisen · Belmont, US
Morten Groenbech Rasch · Haslev, DK
Jianhe Chen · Beijing, CN
Haisun Zhu · Norfolk, US
Rong Zhou · Fullerton, US
Prafull S. Gandhi · Rang Taché Est, DK

Key dates

Filing date	Feb 1, 2018
Grant date	Sep 10, 2024
Priority date	—
Expiry date	Jun 25, 2039

Classification

Technology area (CPC C)Chemistry; Metallurgy
CPC primaryC07K2317/92
WIPO fieldPharmaceuticals
WIPO sectorChemistry

Abstract

The present invention relates to improved procoagulant antibodies including bispecific antibodies capable of binding to coagulation Factor IX (FIX) or the activated form thereof Factor IXa (FIXa) and optionally Factor X (FX) and the activated form thereof Factor Xa (FXa) and promoting FX activation by FIXa, antibodies binding their epitopes and methods and composition for treating subjects suffering from a coagulopathy such as haemophilia A.

Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.